 Kurtis Davies
Concepts (269)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 18 | 2025 | 2526 | 2.800 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 14 | 2024 | 1081 | 2.510 |
Why?
| | Oncogene Proteins, Fusion | 10 | 2021 | 215 | 2.050 |
Why?
| | Proto-Oncogene Proteins | 11 | 2024 | 648 | 1.960 |
Why?
| | High-Throughput Nucleotide Sequencing | 9 | 2025 | 539 | 1.890 |
Why?
| | Protein-Tyrosine Kinases | 8 | 2024 | 434 | 1.890 |
Why?
| | Biomarkers, Tumor | 12 | 2025 | 1276 | 1.620 |
Why?
| | Mutation | 12 | 2024 | 3958 | 1.510 |
Why?
| | Pathology, Molecular | 2 | 2021 | 27 | 1.350 |
Why?
| | Proto-Oncogene Proteins c-met | 2 | 2021 | 75 | 1.250 |
Why?
| | Neoplasms | 8 | 2025 | 2671 | 1.180 |
Why?
| | Protein Kinase Inhibitors | 12 | 2024 | 916 | 1.120 |
Why?
| | Gene Rearrangement | 3 | 2025 | 150 | 1.120 |
Why?
| | Exons | 4 | 2022 | 355 | 1.100 |
Why?
| | Cell-Free Nucleic Acids | 2 | 2025 | 43 | 1.040 |
Why?
| | ErbB Receptors | 6 | 2024 | 614 | 1.000 |
Why?
| | Circulating Tumor DNA | 1 | 2025 | 34 | 0.920 |
Why?
| | Drug Resistance, Neoplasm | 8 | 2024 | 801 | 0.910 |
Why?
| | Endometrial Neoplasms | 2 | 2023 | 201 | 0.830 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 160 | 0.780 |
Why?
| | Pyrazoles | 4 | 2013 | 423 | 0.760 |
Why?
| | Oncogene Fusion | 2 | 2019 | 13 | 0.730 |
Why?
| | Protein Kinases | 3 | 2017 | 319 | 0.730 |
Why?
| | Neoplasms, Muscle Tissue | 1 | 2019 | 4 | 0.620 |
Why?
| | In Situ Hybridization, Fluorescence | 4 | 2018 | 317 | 0.620 |
Why?
| | Immunohistochemistry | 1 | 2023 | 1738 | 0.610 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2019 | 54 | 0.600 |
Why?
| | Gene Fusion | 1 | 2018 | 27 | 0.580 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 2020 | 267 | 0.580 |
Why?
| | DNA, Neoplasm | 1 | 2019 | 164 | 0.580 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2019 | 105 | 0.580 |
Why?
| | Brain Neoplasms | 7 | 2021 | 1238 | 0.580 |
Why?
| | Receptor Protein-Tyrosine Kinases | 5 | 2019 | 234 | 0.560 |
Why?
| | Laboratory Proficiency Testing | 1 | 2016 | 10 | 0.510 |
Why?
| | Antineoplastic Agents | 5 | 2018 | 2129 | 0.500 |
Why?
| | Pyridines | 3 | 2013 | 506 | 0.470 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2015 | 80 | 0.450 |
Why?
| | Humans | 47 | 2025 | 137585 | 0.400 |
Why?
| | Genetic Testing | 1 | 2016 | 460 | 0.400 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2019 | 1079 | 0.400 |
Why?
| | Sodium-Phosphate Cotransporter Proteins, Type IIb | 1 | 2012 | 9 | 0.400 |
Why?
| | Computational Biology | 2 | 2018 | 644 | 0.380 |
Why?
| | Cell Line, Tumor | 13 | 2025 | 3412 | 0.380 |
Why?
| | RNA | 1 | 2019 | 921 | 0.380 |
Why?
| | Glioma | 3 | 2021 | 395 | 0.370 |
Why?
| | Neurons | 4 | 2012 | 1590 | 0.360 |
Why?
| | Cell Proliferation | 8 | 2018 | 2475 | 0.340 |
Why?
| | Hippocampus | 4 | 2008 | 895 | 0.310 |
Why?
| | beta Catenin | 2 | 2023 | 253 | 0.310 |
Why?
| | Synaptic Membranes | 1 | 2008 | 18 | 0.300 |
Why?
| | Subcellular Fractions | 2 | 2008 | 82 | 0.290 |
Why?
| | Pyrimidines | 1 | 2011 | 470 | 0.280 |
Why?
| | Long-Term Synaptic Depression | 1 | 2008 | 56 | 0.280 |
Why?
| | Cell Cycle Proteins | 1 | 2011 | 617 | 0.280 |
Why?
| | Receptors, AMPA | 1 | 2008 | 141 | 0.270 |
Why?
| | DNA Mutational Analysis | 3 | 2023 | 399 | 0.260 |
Why?
| | Glioblastoma | 2 | 2021 | 345 | 0.260 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2007 | 182 | 0.260 |
Why?
| | Head and Neck Neoplasms | 2 | 2025 | 606 | 0.260 |
Why?
| | Nuclear Proteins | 1 | 2011 | 712 | 0.260 |
Why?
| | Molecular Targeted Therapy | 4 | 2018 | 411 | 0.250 |
Why?
| | DNA Polymerase II | 2 | 2023 | 37 | 0.250 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 2 | 2023 | 35 | 0.250 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 1692 | 0.250 |
Why?
| | Liquid Biopsy | 1 | 2025 | 14 | 0.240 |
Why?
| | Signal Transduction | 7 | 2018 | 5079 | 0.240 |
Why?
| | Phosphorylation | 7 | 2015 | 1759 | 0.230 |
Why?
| | Central Nervous System Cysts | 1 | 2025 | 14 | 0.230 |
Why?
| | c-Mer Tyrosine Kinase | 4 | 2018 | 45 | 0.230 |
Why?
| | DNA Copy Number Variations | 3 | 2025 | 182 | 0.230 |
Why?
| | Kelch-Like ECH-Associated Protein 1 | 1 | 2024 | 12 | 0.230 |
Why?
| | Papillomaviridae | 1 | 2025 | 125 | 0.230 |
Why?
| | Female | 24 | 2025 | 73304 | 0.220 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2017 | 224 | 0.220 |
Why?
| | Prognosis | 6 | 2023 | 4030 | 0.220 |
Why?
| | CTLA-4 Antigen | 1 | 2024 | 99 | 0.220 |
Why?
| | Colorectal Neoplasms | 2 | 2022 | 806 | 0.210 |
Why?
| | DNA Mismatch Repair | 1 | 2023 | 49 | 0.210 |
Why?
| | Male | 24 | 2025 | 67762 | 0.200 |
Why?
| | Cell Culture Techniques | 1 | 2025 | 363 | 0.200 |
Why?
| | raf Kinases | 1 | 2021 | 13 | 0.190 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2023 | 528 | 0.180 |
Why?
| | Checkpoint Kinase 1 | 2 | 2011 | 30 | 0.180 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2021 | 15 | 0.180 |
Why?
| | Papillomavirus Infections | 1 | 2025 | 325 | 0.180 |
Why?
| | Drug Synergism | 4 | 2018 | 382 | 0.180 |
Why?
| | Receptor, ErbB-2 | 2 | 2022 | 341 | 0.180 |
Why?
| | Laboratories | 2 | 2025 | 113 | 0.170 |
Why?
| | GTP Phosphohydrolases | 1 | 2020 | 93 | 0.160 |
Why?
| | Microtubule-Associated Proteins | 1 | 2021 | 196 | 0.160 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2019 | 16 | 0.160 |
Why?
| | MAP Kinase Signaling System | 1 | 2021 | 320 | 0.160 |
Why?
| | Middle Aged | 12 | 2025 | 33479 | 0.160 |
Why?
| | Aged | 10 | 2023 | 23961 | 0.150 |
Why?
| | Cell Cycle | 2 | 2012 | 601 | 0.150 |
Why?
| | Carcinoma, Endometrioid | 1 | 2019 | 50 | 0.150 |
Why?
| | Gene Amplification | 2 | 2019 | 104 | 0.140 |
Why?
| | Carcinogenesis | 1 | 2020 | 217 | 0.140 |
Why?
| | Aged, 80 and over | 4 | 2023 | 7635 | 0.140 |
Why?
| | Ependymoma | 1 | 2019 | 165 | 0.140 |
Why?
| | Smokers | 1 | 2018 | 145 | 0.140 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 142 | 0.130 |
Why?
| | Chloroquine | 1 | 2017 | 54 | 0.130 |
Why?
| | Membrane Proteins | 2 | 2020 | 1164 | 0.130 |
Why?
| | Neoplasm Staging | 3 | 2019 | 1389 | 0.130 |
Why?
| | Ganglioglioma | 1 | 2016 | 35 | 0.130 |
Why?
| | Small Molecule Libraries | 1 | 2017 | 94 | 0.130 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 2 | 2013 | 37 | 0.120 |
Why?
| | Rats, Sprague-Dawley | 4 | 2012 | 2486 | 0.120 |
Why?
| | Thyroid Carcinoma, Anaplastic | 1 | 2016 | 34 | 0.120 |
Why?
| | Astrocytoma | 1 | 2016 | 128 | 0.120 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2017 | 872 | 0.120 |
Why?
| | Adult | 9 | 2025 | 37929 | 0.120 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 2 | 2007 | 188 | 0.120 |
Why?
| | Oncogenes | 1 | 2015 | 116 | 0.110 |
Why?
| | Sequence Analysis, RNA | 1 | 2017 | 452 | 0.110 |
Why?
| | Mutation, Missense | 1 | 2016 | 341 | 0.110 |
Why?
| | Genetic Variation | 1 | 2019 | 991 | 0.110 |
Why?
| | Cell Survival | 2 | 2017 | 1120 | 0.110 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2013 | 367 | 0.110 |
Why?
| | Autophagy | 1 | 2017 | 284 | 0.110 |
Why?
| | Health Care Surveys | 1 | 2016 | 565 | 0.110 |
Why?
| | Rats | 5 | 2012 | 5647 | 0.110 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 210 | 0.110 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2016 | 249 | 0.110 |
Why?
| | Biomarkers | 2 | 2024 | 4149 | 0.110 |
Why?
| | Receptor, trkA | 1 | 2013 | 18 | 0.110 |
Why?
| | Melanoma | 1 | 2020 | 760 | 0.100 |
Why?
| | Indoles | 1 | 2017 | 412 | 0.100 |
Why?
| | Antibodies, Monoclonal | 2 | 2024 | 1430 | 0.100 |
Why?
| | Epidermal Growth Factor | 1 | 2013 | 177 | 0.100 |
Why?
| | RNA, Small Interfering | 2 | 2014 | 622 | 0.100 |
Why?
| | Skin Neoplasms | 1 | 2020 | 855 | 0.100 |
Why?
| | Sulfonamides | 1 | 2017 | 513 | 0.100 |
Why?
| | Syndecan-4 | 1 | 2012 | 7 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2016 | 1396 | 0.100 |
Why?
| | Genomics | 1 | 2018 | 795 | 0.100 |
Why?
| | Animals | 10 | 2024 | 36940 | 0.090 |
Why?
| | Thyroid Neoplasms | 1 | 2016 | 343 | 0.090 |
Why?
| | Prospective Studies | 1 | 2023 | 7604 | 0.090 |
Why?
| | Pyrimidinones | 1 | 2011 | 113 | 0.090 |
Why?
| | Databases, Factual | 1 | 2016 | 1357 | 0.090 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 2 | 2012 | 219 | 0.090 |
Why?
| | HeLa Cells | 1 | 2011 | 636 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2022 | 2253 | 0.080 |
Why?
| | DNA Replication | 1 | 2011 | 238 | 0.080 |
Why?
| | Apoptosis | 3 | 2015 | 2553 | 0.080 |
Why?
| | Protein Transport | 2 | 2008 | 445 | 0.080 |
Why?
| | Microdissection | 1 | 2008 | 15 | 0.080 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 5778 | 0.080 |
Why?
| | In Vitro Techniques | 2 | 2008 | 1092 | 0.070 |
Why?
| | Neoplasm Grading | 2 | 2020 | 307 | 0.070 |
Why?
| | Cohort Studies | 1 | 2018 | 5742 | 0.070 |
Why?
| | Carboplatin | 2 | 2020 | 144 | 0.070 |
Why?
| | Threonine | 1 | 2007 | 47 | 0.070 |
Why?
| | Follow-Up Studies | 3 | 2020 | 5131 | 0.060 |
Why?
| | Mice, Nude | 2 | 2018 | 698 | 0.060 |
Why?
| | Neuronal Plasticity | 1 | 2008 | 290 | 0.060 |
Why?
| | Mice | 4 | 2024 | 17787 | 0.060 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1236 | 0.060 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2025 | 49 | 0.060 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2025 | 20 | 0.060 |
Why?
| | Sella Turcica | 1 | 2025 | 18 | 0.060 |
Why?
| | Survival Rate | 2 | 2020 | 1972 | 0.060 |
Why?
| | Salivary Glands | 1 | 2025 | 33 | 0.060 |
Why?
| | Infant | 4 | 2020 | 9465 | 0.060 |
Why?
| | Coculture Techniques | 1 | 2025 | 239 | 0.060 |
Why?
| | Synapses | 1 | 2008 | 427 | 0.060 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2024 | 106 | 0.060 |
Why?
| | Genes, Tumor Suppressor | 1 | 2024 | 86 | 0.060 |
Why?
| | Piperazines | 2 | 2018 | 350 | 0.060 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2024 | 173 | 0.050 |
Why?
| | Biological Products | 1 | 2007 | 216 | 0.050 |
Why?
| | Analysis of Variance | 1 | 2007 | 1316 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2025 | 2189 | 0.050 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 658 | 0.050 |
Why?
| | Ischemia | 1 | 2007 | 409 | 0.050 |
Why?
| | B7-H1 Antigen | 1 | 2024 | 217 | 0.050 |
Why?
| | Tumor Suppressor Proteins | 1 | 2024 | 327 | 0.050 |
Why?
| | Flow Cytometry | 1 | 2025 | 1178 | 0.050 |
Why?
| | Retrospective Studies | 4 | 2020 | 15657 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2025 | 1050 | 0.040 |
Why?
| | Vinblastine | 1 | 2020 | 71 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 674 | 0.040 |
Why?
| | Standard of Care | 1 | 2020 | 72 | 0.040 |
Why?
| | Protein Tyrosine Phosphatases | 2 | 2012 | 172 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2019 | 42 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 95 | 0.040 |
Why?
| | Models, Molecular | 2 | 2018 | 1570 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 35 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2020 | 6079 | 0.040 |
Why?
| | Phthalazines | 1 | 2018 | 45 | 0.040 |
Why?
| | Cetuximab | 1 | 2018 | 98 | 0.040 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 167 | 0.030 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2017 | 27 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2007 | 2607 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2017 | 36 | 0.030 |
Why?
| | Quality Control | 1 | 2017 | 172 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2018 | 570 | 0.030 |
Why?
| | Child | 3 | 2021 | 21935 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2013 | 2900 | 0.030 |
Why?
| | Workflow | 1 | 2017 | 165 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2024 | 1996 | 0.030 |
Why?
| | Cell Cycle Checkpoints | 1 | 2016 | 98 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 307 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2017 | 229 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 976 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2014 | 34 | 0.030 |
Why?
| | Oncogene Protein v-akt | 1 | 2014 | 24 | 0.030 |
Why?
| | Child, Preschool | 2 | 2020 | 11074 | 0.030 |
Why?
| | STAT6 Transcription Factor | 1 | 2014 | 27 | 0.030 |
Why?
| | Phosphatidylserines | 1 | 2014 | 91 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 730 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2016 | 510 | 0.030 |
Why?
| | Platelet Aggregation | 1 | 2014 | 103 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 812 | 0.030 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2019 | 683 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2014 | 152 | 0.030 |
Why?
| | Drug Resistance | 1 | 2014 | 169 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2014 | 185 | 0.030 |
Why?
| | Adenine | 1 | 2015 | 271 | 0.030 |
Why?
| | Neovascularization, Pathologic | 1 | 2014 | 301 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2018 | 10811 | 0.020 |
Why?
| | Memantine | 1 | 2012 | 14 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2017 | 1946 | 0.020 |
Why?
| | N-Methylaspartate | 1 | 2012 | 40 | 0.020 |
Why?
| | Down-Regulation | 1 | 2014 | 657 | 0.020 |
Why?
| | Transcriptome | 1 | 2018 | 971 | 0.020 |
Why?
| | Adolescent | 2 | 2021 | 21513 | 0.020 |
Why?
| | Caspase 3 | 1 | 2012 | 246 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3556 | 0.020 |
Why?
| | Neoplastic Stem Cells | 1 | 2015 | 399 | 0.020 |
Why?
| | Biological Transport | 1 | 2012 | 418 | 0.020 |
Why?
| | Receptors, GABA-A | 1 | 2012 | 142 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 2057 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2013 | 430 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2012 | 810 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1774 | 0.020 |
Why?
| | Long-Term Potentiation | 1 | 2012 | 198 | 0.020 |
Why?
| | Synaptic Transmission | 1 | 2012 | 289 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2016 | 900 | 0.020 |
Why?
| | Time Factors | 1 | 2020 | 6828 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2017 | 3284 | 0.020 |
Why?
| | Phenanthrolines | 1 | 2008 | 7 | 0.020 |
Why?
| | Bicuculline | 1 | 2008 | 23 | 0.020 |
Why?
| | GABA Antagonists | 1 | 2008 | 35 | 0.020 |
Why?
| | Biophysical Phenomena | 1 | 2008 | 64 | 0.020 |
Why?
| | Immunity, Innate | 1 | 2014 | 828 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2008 | 155 | 0.020 |
Why?
| | Quinoxalines | 1 | 2008 | 66 | 0.020 |
Why?
| | Excitatory Postsynaptic Potentials | 1 | 2008 | 124 | 0.020 |
Why?
| | United States | 1 | 2025 | 14841 | 0.020 |
Why?
| | Tyrosine | 1 | 2008 | 222 | 0.020 |
Why?
| | Spodoptera | 1 | 2007 | 40 | 0.020 |
Why?
| | Patch-Clamp Techniques | 1 | 2008 | 286 | 0.020 |
Why?
| | Protein Subunits | 1 | 2008 | 239 | 0.020 |
Why?
| | Organometallic Compounds | 1 | 2008 | 111 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2007 | 372 | 0.020 |
Why?
| | Glutamic Acid | 1 | 2008 | 246 | 0.020 |
Why?
| | Rats, Wistar | 1 | 2007 | 455 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2007 | 861 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2015 | 4295 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2007 | 2139 | 0.010 |
Why?
| | Cell Line | 1 | 2007 | 2847 | 0.010 |
Why?
| | Peptides | 1 | 2007 | 985 | 0.010 |
Why?
| | Young Adult | 1 | 2018 | 13209 | 0.010 |
Why?
| | Islets of Langerhans | 1 | 2007 | 803 | 0.010 |
Why?
| | Protein Binding | 1 | 2007 | 2224 | 0.010 |
Why?
| | Insulin | 1 | 2007 | 2409 | 0.010 |
Why?
|
|
Davies's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|